Status:
COMPLETED
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
Conditions:
HIV Infection
Eligibility:
All Genders
Brief Summary
This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent ...
Detailed Description
Numerous studies have demonstrated an association between HLA class I genotypes with differing progression to AIDS in individuals who are followed after being off antiretroviral therapy. These studies...
Eligibility Criteria
Inclusion
- HLA-Class I HLA-B\*27, B\*35, B\*53 and/or B\*57 positive identified through the REACH study
- Subject's ability and willingness to provide written informed consent
- Subject's ability and willingness to be followed at least one year on this ATN 026 study
Exclusion
- On chronic immunosuppressive therapy, not including topical or inhaled steroid use.
- Any prohibited medication listed in protocol within 2 weeks prior to the Entry visit labs
Key Trial Info
Start Date :
December 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00107029
Start Date
December 1 2002
End Date
September 1 2005
Last Update
February 28 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
2
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010
3
Children's Diagnostic and Treatment Center
Fort Lauderdale, Florida, United States, 33101
4
University of Miami-Jackson Memorial Medical Center
Miami, Florida, United States, 33101